Nasal immune responses to respiratory viruses in immunocompromised and healthy adults
Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts
Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07295535
See how nasal immune responses to respiratory viruses differ between immunocompromised adults and healthy adults.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia (other) |
| Locations | 1 site (Pavia, Pavia) |
| Trial ID | NCT07295535 on ClinicalTrials.gov |
What this trial studies
This observational study will compare nasal mucosal immunity to respiratory viruses, including SARS-CoV-2, in immunocompromised adults and healthy volunteers aged 18–90. Researchers will collect nasal samples and perform laboratory immune measurements to characterize immune cell composition and virus-specific responses in the upper airway. The study aims to describe how specific responses develop and how long they persist in different participant groups. Findings will be used to better understand how underlying immune impairment or immunosuppressive treatments alter local antiviral immunity.
Who should consider this trial
Good fit: Adults 18–90 who can give informed consent and are either healthy with no history of immunodeficiency or immunosuppressed due to medical conditions or treatments (for example transplant recipients or those on immunosuppressive therapy).
Not a fit: Pregnant or lactating women, minors, and individuals unable to provide informed consent are excluded and therefore would not benefit from participation.
Why it matters
Potential benefit: If successful, the findings could help guide strategies to better protect immunocompromised people, including tailoring vaccination or treatment approaches.
How similar studies have performed: Prior observational work has described nasal mucosal responses to respiratory viruses in healthy people and some immunocompromised groups, but comprehensive comparisons across diverse immunosuppressed populations remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed Consent: Participants must have signed an informed consent form. * Age Range: Participants aged between 18 and 90 years. * Healthy Immunocompetent Donors: no underlying medical conditions declared, no clinical history of immunodeficiency or use of immunosuppressive medications. * Immunocompromised Patients: subjects with medical conditions or treatments associated with significant impairment of the immune system. This may include organ or stem cell transplants, ongoing immunosuppressive therapies, documented genetic immunosuppression. Exclusion Criteria: * Pregnant or lactating women. * Individuals unable to provide informed consent
Where this trial is running
Pavia, Pavia
- Fondazione IRCCS Policlinico San Matteo di Pavia — Pavia, Pavia, Italy (RECRUITING)
Study contacts
- Study coordinator: Stefania Mantovani, MSc
- Email: s.mantovani@smatteo.pv.it
- Phone: 0039 0382501808
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Immuno-modulation, Immuno-suppression, Immunocompromised Patients, Healthy Subjects, Oncological Patients